Every trading day, be ready to attack the market instead of reacting to the
market.

You will know where the key technical resistance and support levels are and what
the market is likely to do next. iStock will arm you with a target list of stocks
to buy and sell - right now - based on our exclusive, proprietary trading models.
You will also receive monthly ETF model portfolio and trend trader model portfolio

Mylan Laboratories Ltd. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg. Mylan is shipping this product immediately.

Atorvastatin Calcium is the generic version of Pfizer's Lipitor Tablets, which are indicated as an adjunct to diet in patients with primary hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL cholesterol.

Earlier this month, Mylan announced the launch of the generic version of Lipitor in France, Belgium, the UK, the Netherlands and Ireland. Lipitor had U.S. sales of $8.1 billion for the twelve months ending March 31, 2012, according to IMS Health.

On Thursday, Mylan announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy. Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.

On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.

The company announced the launch of generic version of Sanofi-Aventis' (NYSE:SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. has received final clearance from the U.S. health regulators for its ANDA for Clopidogrel Tablets USP, 75 mg and 300 mg.

MYL is trading up 0.79% at $21.80 on Tuesday. The stock has been trading between $15.49 and $25 for the past 52 weeks.

Fundamental data is provided by Zacks
Investment Research, and Commentary, news and Press Releases provided by
YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not
intended for trading purposes or advice. iStockAnalyst.com is not an investment
adviser and does not provide, endorse or review any information or data contained
herein.
The blog articles are opinions by respective blogger. By using this site you are
agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither
iStockAnalyst nor any of its independent providers is liable for any informational
errors, incompleteness, or delays, or for any actions taken in reliance on information
contained herein. You are solely responsible for the investment decisions made by
you and the consequences resulting therefrom. By accessing the iStockAnalyst.com
site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based
on EOD data.